ArticlePharmaceutics2019
Repurposing Dihydropyridines for Treatment of
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Discovery of Sesamolin as a Potential Anti-ACS omega · 2025Article
- Natural products based on Correa's cascade for the treatment of gastric cancer trilogy: Current status and future perspective.Journal of pharmaceutical analysis · 2025Review
- MT1G promotes iron autophagy and inhibits the function of gastric cancer cell lines by intervening in GPX4/SQSTM1.Scientific reports · 2024Article
- Novel Drug-like HsrA Inhibitors Exhibit Potent Narrow-Spectrum Antimicrobial Activities againstInternational journal of molecular sciences · 2024Article
- Signaling pathways of oxidative stress response: the potential therapeutic targets in gastric cancer.Frontiers in immunology · 2023Review
- Insights into the Orchestration of Gene Transcription Regulators inInternational journal of molecular sciences · 2022Review
- 1,4-Dihydropyridine as a Promising Scaffold for Novel Antimicrobials AgainstFrontiers in microbiology · 2022Article
- Review
- Targeting the Essential Transcription Factor HP1043 ofFrontiers in molecular biosciences · 2022Article
- Two-component regulatory systems inFrontiers in cellular and infection microbiology · 2022Review
- Definition of the Binding Architecture to a Target Promoter of HP1043, the Essential Master Regulator ofInternational journal of molecular sciences · 2021Article
- Evaluation of Physicochemical Properties of Amphiphilic 1,4-Dihydropyridines and Preparation of Magnetoliposomes.Nanomaterials (Basel, Switzerland) · 2021Article
- Autophagy in Gastric Mucosa: The Dual Role and Potential Therapeutic Target.BioMed research international · 2021Review
- Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2020Review
- Small Molecule Inhibitors of the Response Regulator ArsR Exhibit Bactericidal Activity againstMicroorganisms · 2020Article
- Flavodoxins as Novel Therapeutic Targets againstInternational journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance is a major cause of the increasing failures in the current eradication therapies against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.